Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial

BACKGROUND: Diarrhea-predominant irritable bowel syndrome (IBS-D) impairs patient quality of life (QOL). Rifaximin is an oral, nonsystemic antibiotic indicated for IBS-D. The objective of this secondary analysis was to evaluate rifaximin retreatment on IBS-related QOL in patients with IBS-D. METHODS...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Therap Adv Gastroenterol
Asıl Yazarlar: Cash, Brooks D., Pimentel, Mark, Rao, Satish S. C., Weinstock, Leonard, Chang, Lin, Heimanson, Zeev, Lembo, Anthony
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: SAGE Publications 2017
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5598815/
https://ncbi.nlm.nih.gov/pubmed/28932270
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756283X17726087
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller